Neolactoferrin rushes to the market
A participant of the Skolkovo Foundation creates a unique drug – Neolactoferrin
When used together with antibiotics, the drug significantly increases the effect of their action.
More than a dozen companies are engaged in research in the field of gene technologies at Skolkovo. Transgenpharm LLC, having become a resident of Skolkovo, proposed to implement a project to create a bio–production of a domestic human protein - lactoferrin contained in women's milk. A wide range of its bactericidal properties protects infants from infections until they develop their own mechanism of immunological protection. For many months, in the Cluster of Biomedical Technologies of the Skolkovo Innovation Center, the project of creating lactoferrin was discussed at the level of highly qualified managers, as a result of which a "roadmap" appeared. In particular, the project was divided into two components: the production of human lactoferrin as an active food additive and as a component of highly effective biologically safe medicines of a new generation.
Photo from the website of the company "Transgenpharm"
The joint work of specialists of the Skolkovo Innovation Center and employees of Transgenpharm LLC, which determined the main directions of scientific and technological research, was crowned with success in 2011. For the first time, a commercial product was created – human lactoferrin – "Neolactoferrin". It has been tested in leading Russian research centers and centers of biological and medical profile. It has been proven that the drug stimulates natural immunity, is absolutely harmless, does not contain GMO components, does not accumulate in the human body, and is compatible with almost any food and medicines. An environmentally friendly and economical technology of multi-tonnage production of packaged and encapsulated "Neolactoferrin" has been developed, which has also received state certificates for its use as a component of food products, including baby food.
Now there is an opportunity to make up for the deficiency of this bactericidal protein in the nutrition of newborn children who are partially or fully artificially fed throughout Russia from Kaliningrad to Sakhalin, which will solve the important social task of preserving the health of our children. It is planned to start research on the use of "Neolactoferrin" in providing anti-infective protection of premature babies at the Scientific Center for Children's Health.
According to Viktor Vekselberg, President of the Skolkovo Innovation Center, "the commercialization of scientific developments will become the locomotive of Russia's innovative industrialization."
Andrey Komolov, Investment Director of the Biomedical Technologies Cluster, noted: "Everyone knows about lactoferrin today. The main problem was that no one could stabilize it. To date, our genetic engineers have been able to inoculate this gene in a goat and have received goat's milk with human lactoferrin, which is not present in artificial mixtures and which newborn babies do not receive in the absence of breast milk feeding."
In autumn 2012, the Skolkovo Foundation will organize a specialized international conference dedicated to the use of lactoferrin in neonatology. Encapsulated "Neolactoferrin" (to protect protein from the aggressive environment of the stomach) can be used as an element of functional nutrition of adults due to its antioxidant and immune-strengthening properties.
To date, lactoferrin obtained from cow's milk has been used. Animal lactoferrin differs from human lactoferrin, so "Neolactoferrin" will have more opportunities for use not only in dietetics, but also in medicine. Preclinical studies of Neolactoferrin have already been successfully launched, followed by clinical trials.
There is no human lactoferrin as a marketable product on the world market. Therefore, the success of this project will allow us to occupy our niche in the global biotechnology market. The Skolkovo Foundation is helping to organize the Neolactoferrin market, which this year will be presented to the public at major international forums in Japan, Canada and the USA.
Portal "Eternal youth" http://vechnayamolodost.ru
07.03.2012